Thompson Davis & Co’s Viridian Therapeutics VRDN Stock Holding History

Thompson Davis & Co’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-47	Closed	-$8K	–	1171
2015 Q4	$8K	Buy	+47	New	+$9.05K	0.01%	726

Other funds holding VRDN

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ICAS

Investors Capital Advisory Services Lynnfield, Massachusetts $521M AUM 1.51% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Thompson Davis & Co's VRDN Position: Q1 2016 in Review

Thompson Davis & Co sold out of Viridian Therapeutics (VRDN) in Q1 2016, closing a stake of 47 shares — an estimated $8K sold.

Thompson Davis & Co first reported a position in VRDN in Q4 2015 and held it in 1 quarter. The position peaked at $8K in Q4 2015. 9 funds tracked by Wall St. Rank hold VRDN as of Q1 2016.

Thompson Davis & Co reported no remaining Viridian Therapeutics position as of Q1 2016 after selling out during the quarter.
Thompson Davis & Co sold 47 Viridian Therapeutics shares in Q1 2016, an estimated $8K.
Thompson Davis & Co first reported a position in Viridian Therapeutics in Q4 2015 and held it in 1 quarter.
Thompson Davis & Co's Viridian Therapeutics position peaked at $8K in Q4 2015.
9 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2016.

Based on Thompson Davis & Co's 13F filing for Q1 2016, filed 2 May 2016.